ArticleScientific reports2025
Effect of etofenamate on midline closure defect in early chicken embryos: an experimental study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the effect of etofenamate, a nonsteroidal anti-inflammatory drug, on the development of midline closure defects in early chick embryos. The study was conducted at the Animal Laboratory of the Department of Animal Science, Faculty of Agriculture, Kahramanmaraş Sütçü İmam University. A total of 80 fertilized, pathogen-free, day-zero Broiler chicken eggs were used. The eggs were incubated for 24 h at 37.8 ± 0.2 °C with 65-75% humidity in an incubator with an automatic turning system. Subsequently, a 0.3 cm window was made in the eggs, and the eggs were randomly divided into four main groups and administered different doses of etofenamate (1, 2, 4 mg/day). On the 10th day of incubation, embryos were evaluated macroscopically, and those showing developmental delay or being unfertilized were excluded. Histological samples were taken from the brain and spinal cord regions of developed embryos to assess neural tube formation. In the control group, neural tube closure occurred in 95% of the embryos, while one embryo (5%) in the low-dose etofenamate group exhibited a neural tube defect. No neural tube defects were observed in the medium and high-dose groups; however, both groups showed a 25% rate of early embryonic death. The results indicate that etofenamate may negatively affect neural tube development at low doses, with the effect varying depending on the dose, and that higher doses increase the risk of embryonic death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.